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PP-095 Dynamics of serum HBV DNA levels and MELD
scores in fatal acute-on-chronic hepatitis B liver
failure
J. Lai1 *, D.-Y. Xie1, T.-Y. Chong1, Z.-G. Yao2, Q.-W. Mo1.
1Department of Infectious Diseases, The Third Afﬁliated
Hospital, Sun Yat-Sen University, 2The People’s Hospital of
Yangjiang, China
Background and Aims: Until now, it is still not very clear
what impact the progression and result in fatal outcomes
of acute-on-chronic hepatitis B liver failure (HB-ACLF).
Model for end-stage liver disease (MELD) scores system is
an internationally recognized to predict the pathogenetic
condition of the end-stage liver disease. The study is to
investigate the dynamics and clinical signiﬁcances of serum
HBV DNA levels and MELD scores in the terminal phase of
HB-ACLF.
Methods: 106 fatal patients with HB-ACLF were enrolled,
who had never accepted antiviral therapy or liver
transplantation. At three phases of 29 90 d, 8 28 d and
1 7 d before death, they were detected serum HBV DNA
levels by Realtime-PCR in order meanwhile MELD scores
were calculated.
Results: In 35 patients with HBeAg positive, HBV DNA levels
were 6.16±1.59 log10, 5.63±1.52 log10 and 5.12±2.13
log10 copies/ml while MELD scores were 19.03±7.51,
24.79±6.40 and 33.06±7.64 respectively. In 71 patients with
anti-HBe positive, HBV DNA levels were 4.63±1.82 log10,
5.77±1.74 log10 and 4.69±1.68 log10 copies/ml while MELD
scores were 24.01±6.32, 28.34±7.77 and 33.25±10.13 in
sequence. HBV DNA levels of HBeAg positive group were
signiﬁcantly higher than that of anti-HBe positive group at
the phase of 29 90 d (P < 0.05). But in the same group,
HBV DNA levels were no signiﬁcant difference among
three phases, regardless of HBVe system status. With the
exacerbation of the ill, MELD scores increased steadily and
signiﬁcant difference was found in all patients (P < 0.05).
Conclusions: To initiate HB-ACLF occurrence, HBeAg
positive patients need higher serum HBV DNA levels than
that of anti-HBe positive ones. Regardless of HBVe system
status, sustained high HBV DNA levels may promote the
disease worsened and be fatal to patients.
PP-096 Different clinical features of spontaneous
decrease of HBV DNA level between
HBeAg-positive and HBeAg-negative chronic
hepatitis B patients
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Background: To compare the clinical features of
spontaneous decrease of HBV DNA level between Hepatitis B
e antigen (HBeAg)-positive and HBeAg-negative chronic
hepatitis B patients (CHB).
Methods: Dynamic change of HBV DNA level was observed
for 12 weeks in 315 cases with admission HBV DNA level
above 10,000 copies/mL. All patients had never been
treated with antiviral or immunoregulatory drugs during
this period. In the ﬁrst observation week, HBV DNA, HBeAg,
ALT, AST, total bilirubin (TBIL), prothrombin time (PT)
were detected. HBV DNA was redetected at the end of
observation period. These cases were divided into subgroups
according to HBeAg and HBV DNA decrease (HBeAg-negative
group, HBeAg-positive group, and each was subgrouped into
decreased subgroup and non-decreased subgroup).
Results: Among the 315 CHB patients, 171 patients (54.3%)
underwent spontaneous decrease of HBV DNA level within
12 weeks. 83 (55.0%) of 151 HBeAg-positive patients
underwent spontaneous decrease of HBV DNA level, while
88 (53.7%) of 164 HBeAg-negative patients underwent that.
The difference between the above two groups was not
signiﬁcant (c2 = 0.054, P = 0.816). Among HBeAg-positive
patients, AST, TBIL, PT were higher in patients with
spontaneous decrease of HBV DNA level than in those
without (t = 3.485- 4.156, P = 0.000 0.001). Among HBeAg-
negative patients, HBV DNA, ALT, AST, TBIL, PT were higher
in patients with spontaneous decrease of HBV DNA level than
in those withoutv (t = 5.224 2.476, P = 0.000 0.014).
Conclusion: Half of the observed CHB patients underwent
spontaneous decrease of HBV DNA level, and the worse the
hepatic function was, the higher incidence of spontaneous
decrease of HBV DNA level would be whenever HBeAg were
positive or not.
PP-097 A time delay anti-HBV infection treatment
mathematical model with adefovir
Y.T. Wu1, Y.M. Su1 *, L.Q. Min1. 1Mathematics and Physics
School, University of Science and Technology Beijing,
Beijing, China
Background: The time delay mathematical models are
often used to describe the process of HBV infection
and treatment. Based on the basic virus infection model
introduced by Nowak et al. and Park Soo’s data of adefovir,
we set up a time delay model to simulate the dynamic
behavior of free viral, here the time delay stands for the
time between viral entry into a target cell and production
of new virus particles.
Methods: The model is described by three variables: x,
y, v represent the numbers of susceptible cells, infected
cells, and free virus. The model include 12 parameters:
l, d, c, h, b, a, n, k, u, xmax, t, e-mt, where c is the
maximum proliferation rate of target cells, xmax is the
x population density at which proliferation shuts off, h and n
represent the efﬁcacy of the therapy, e-mt accounts for
cells that are infected at time t but die before becoming
productively infected t time units later, the meanings of
l, d, b, a, k, u are the same as those given in Nowak’s
model. During treatment, we chose { l, d, c, h, b, a, n, k,
u, xmax, t, e-mt} = {2.525×102, 3.79e-004, 3×10 6, 0.5,
40, 1.644e-003, 0.9999, 0.0749, 0.1679, 6.6623e+005, 1.8,
e-0.00002×1.8}.
Results: The simulation data of the free viral in our model
is consistent with the clinical data perfectly.
Conclusion: The result shows that our time delay anti-
HBV model may be used as a reference for comparing
the efﬁciency of different drugs, and other HBV infection
models.
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Background: Asymptomatic CK elevations were observed in
patients who received the telbivudine treatment. This study
is to analyze the factors related to this phenomenon.
Poster Presentations, Poster Session Hepatitis B S73
Methods: 78 chronic hepatitis B patients who were
given telbivudine 600mg daily were divided in different
groups according to the sex, age, HBeAg seroconversion,
biochemical response and virological response. The rate and
average of CK elevation were analyzed in these groups.
Results: CK elevation was observed in 61.54% patients
(48/78), 69.12% in male (47/68), 10% in female (1/10),
46.15% in seroconversion group (6/13), 60.98% in SVR group
(25/41). High CK elevation (3 times higher then average)
was observed in 4 patients with kinetic intensity during the
treatment.
Conclusion: Sex and seroconversion are the factors related
to CK elevation during telbivudine treatment and the kinetic
intensity is related to high CK elevation level.
PP-099 Evaluating the immunogenicity of TGF-b1
antigen peptide coupled-KLH as anti-hepatic
ﬁbrosis vaccine
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Objective: To lay a foundation for the further development
of a novel vaccine based on TGF-b1, a pivotal cytokine,
leading to hepatic ﬁbrosis, we detected the neutralization
activity and evaluated anti-liver ﬁbrosis activity by keyhole
limpet hemocyanin (KLH) coupled TGF-b1 domain antigen
peptide vaccine.
Methods: Possible TGF-b1 domain B-cell epitope was
predicted by bioinformatics, then KLH-coupled peptide was
synthesized by the FMOC method. Hepatic injury model rats
were induced by CCl4 for 10 weeks. 40 male SD rats were
randomly divided into four groups: normal group (olive oil),
adjuvant group (freund’s adjuvant), vaccine group (50 mg
TGF-b1 peptide vaccine+CCl4), model group (CCl4). Serum
TGF-b1 antibody, HA, IV-C, ALT, AST, TBIL, ALB and GLB were
detected; Levels of Hydroxyproline in hepatic tissue were
measured and liver tissues were obtained for pathological
observation.
Results: A certain amount of serum antibody was induced by
TGF-b1 peptide vaccine in vaccine group, but no signiﬁcantly
different statistics were observed compared to other groups
(P> 0.05). The data showed high levels of ALT, TBIL, HA, IV-C
and Hyp in both of model and vaccine groups compared
with normal group respectively (P< 0.05). The ALT, AST and
TBIL levels in vaccine group were lower than model group
(P< 0.05), but HA, IV-C and Hyp content were no statistical
signiﬁcances (P> 0.05). HE and VG staining showed different
degree hepatic ﬁbrosis in model and vaccine groups.
Conclusions: TGF-b1 peptide vaccine cannot remarkably
stimulate antibody production, but the liver function of
vaccine group can be mitigated to some extent.
PP-100 Simulation of clinical data under the therapy of
adefovir by mathematical model
L. Meng1, Y.M. Su1 *, L.Q. Min1. 1University of Science and
Technology Beijing, China
Background: Based on the existing model of virus infection,
we bring up a new model which has logistic growth term and
loss of free virus term caused by virus’s entering uninfected
cells. In this presentation, we do an individual simulation
with the new model to test the consistency of clinical and
simulation data.
Methods: The patient has received a 96 weeks therapy of
Adefovir. The model was described with three variables:
x, y, v and 7 parameters: l, d, b, a, u, p, M, k where p, M
represent uninfected cells’ growth rate and environmental
carrying capacity respectively and the other symbols have
the same meaning as those in the basic Nowak model. We
chose {lambda, d, b, a, u, p, M, k} = {1.2067e+6, 0.0181,
0.1158, 0.0217, 0.1600, 0.0163, 6.6667e+012, 0.0140}.
Results: The clinical data and simulation result are
presented in Table 1.
Conclusion: The simulation data is relatively consistent
with clinical data which means our model can capture the
dynamic character of HBV virus to some extent.
Acknowledgment: This paper is jointly supported by the
Fundamental Research Funds for the Central Universities
(No 06108040) and the Key Special Project of China
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Research Program of China.
Table 1: HBV DNA (log copies/ml)
Virus load/weeks 0 12 24 36 48 60 72 84 96
Clinical data 1.27e8 7.78e4 2.28e4 2.28e4 1.84e4 1.22e4 7.73e2 250 250
Simulation data 1.27e8 6.74e5 1.83e5 4.97e4 1.35e4 3.68e3 1.00e3 273.03 74.32
PP-101 A dynamic model of entecavir therapy and after
therapy for HBV Infection
X.J. Zhuo1 *. 1School of Science, Beijing University of Posts
and Telecommunications, China
Background: Entecavir (ETV) is believed to reduce
covalently closed circular DNA. Leonieke et. al gave some
patients’ clinical data of 28 days’ therapy of ETV and the
data after withdraw of therapy. Leonieke et. al also simu-
lated the data by bi-phasic model, but the bi-phasic model
was only simpliﬁcation of Nowak’s basic model under some
conditions. Based on Leonieke et. al’s data and Nowak’s
model, we formulate a new dynamic model to simulate one
patient’s data during and after the ETV therapy.
Methods: A model of HBV is described by four variables: x,
y, v, e, representing uninfected cells, infected cells, free
virus, and immune cells. The model includes 10 parameters:
l, d, b, a, p, k, u, k2, k3, k4 where the meanings of l, d, b,
a, p, k, u are the same as those given in Nowak’s model, k2
represents the curative effect, k3, k4 are relevant to the
immune.
We chose the following parameters during treatment: {l, d,
b, a, p, u, k, k2, k3, k4, k5} = {4.621e5, 6.9e-3, 2.19e-11,
7.3e-3, 1.5e-4, 0.45, 2.37, 2.18, 3e-8, 3.65e-10, 0.1154}.
When the therapy was stopped, we chose {a, u, k2} =
{6.9e-3, 0.25, 0} in which k2 = 0 implies no therapy effect,
a, u becoming smaller means the die rate of infected cells
and free virus decrease after treatment.
Results: Our dynamic model can simulate the patient’s
clinical data during the course of treatment and the rebound
of HBV DNA after withdraw of therapy well.
Conclusion: The difference between the therapy and
withdraw of therapy can be embodied by our model, which
shows our model may possibly capture the dynamics of
anti-HBV infection treatment with ETV.
PP-102 A time-delay HBV therapy mathematical model
for entecavir and adefovir
Y.M. Su1 *, L.Q. Min1. 1School of Mathematics and Physics,
University of Science and Technology Beijing, China
Background: Entecavir (ETV) and Adefovir dipivoxil (AD)
are often used for HBV infection therapy. The use of
Mathematical models to interpret the experimental and
clinical data has made a signiﬁcant contribution to anti-HBV
infections. Based on Jurrien et al’s experimental data with
AD and ETV, considering the time delay of therapy effect
and antiviral drug resistance, we set up a mathematical
model with time delay to simulate the viral dynamics under
the therapy of ETV and AD.
